Program
Anti-GARP Monoclonal Antibody PBA-0111
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Pure Biologics.
Furthest: early phase 1, since Nov 19, 20241 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pure Biologics | 11 open or running | early phase 1since Nov 19, 2024 | Nov 19, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2024First study: early phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT06700070 · 12 planned · United States
TargetBeta
“An afucosylated human monoclonal antibody directed against the transforming growth factor beta (TGF-beta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06700070Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Recruiting | Dec 2025 | 12 |
How it is read
Names in the registry
- “PBA-0111”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.